rare cholestatic liver diseases | News Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

108,176 results for “rare cholestatic liver diseases”

Bylvay Shows Sustained Improvement in Itch and Bile Acid Levels in Rare Cholestatic Liver Diseases

Odevixibat Demonstrates Sustained Improvement in Pruritus and Bile Acid Levels in Rare Cholestatic Liver Diseases

Ipsen's Kayfanda (Odevixibat) Receives EU Approval for Cholestatic Pruritus in Alagille Syndrome

Ipsen Secures Dual CHMP Approvals for Rare Liver Disease Treatments Following Regulatory Strategy Shift

Odevixibat Demonstrates Sustained Improvement in Pruritus and Bile Acid Levels in PFIC and ALGS Patients

Ipsen's Iqirvo Receives U.S. FDA Accelerated Approval for Primary Biliary Cholangitis Treatment

GENFIT Showcases ACLF Pipeline Advances at AASLD 2025 with Three Novel Therapeutic Programs

CANbridge Pharmaceuticals Secures $12.7M Strategic Investment from Baheal Medical to Accelerate Rare Disease Drug Commercialization

Bylvay Demonstrates Sustained Improvement in Itch and Bile Acid Levels in PFIC and ALGS Patients

FDA Approves Tablet Formulation of LIVMARLI for Rare Pediatric Liver Diseases

Page 1 of 1564